Navigating challenges in ADC development

Antibody-Drug Conjugates (ADCs) are notoriously tricky to develop, due to their delicate nature and the barriers facing their delivery. Andreas Dreps, Senior Vice President, Drug Development Services at ICON Biotech, highlights key obstacles in the development of ADCs and why the future remains bright for this targeted therapy, as he explores:

Tumor heterogeneity, resistance and off-target effects
Delicate nature of ADCs
Need for highly refined manufacturing protocols
Advances in linker chemistry, design and manufacturing of mABs
ADCs as a neoadjuvant therapy in breast cancer

Read the Article

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By completing this form you agree ICON may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy. By clicking submit, you consent to allow Citeline to store and process the information submitted to provide you the content requested. They are subject to their Terms and Conditions.

Please complete all required fields to access the content!

Future-Ready Pharmacovigilance: Integrating AI With FDA's EDSTP Guidelines

Join IQVIA’s esteemed panel of experts for an in-depth discussion on how AI can meet and exceed these new expectations. This webinar delves into the intersection of regulatory frameworks and technological innovation, offering insights into the future of PV and how organizations can navigate this transformative field. Key takeaways include:

Accelerating Biologics Development With Strategies For Success

The biologics market is growing rapidly, unlocking exciting opportunities but also presenting significant challenges. Developers are undergoing pressure to accelerate the delivery of innovative therapies while addressing complex regulatory demands, navigating demanding clinical trial phases, efficiently scaling production, and maintaining quality. In this webinar, industry experts will share practical strategies and real-world examples to help you navigate these challenges. Key takeaways:

A New Era of Participant Payment Services

Financial burdens are cited as one of the main barriers to clinical trial recruitment and retention, with traditional methods proving unreliable, complicated and slow. For trial sites and sponsors, the administration burden can be overwhelming, especially on a global scale. Discover how IQVIA’s Participant Payment service is transforming the participant payment landscape, simplifying the process and driving clinical trial success, by offering: